Search

Your search keyword '"Ghiotto, Natascia"' showing total 195 results
Start Over Author "Ghiotto, Natascia"
195 results on '"Ghiotto, Natascia"'

2. Expression of miR-155 in monocytes of people with migraine: association with phenotype, disease severity and inflammatory profile

Author

Greco, Rosaria, Bighiani, Federico, Demartini, Chiara, Zanaboni, Annamaria, Francavilla, Miriam, Facchetti, Sara, Vaghi, Gloria, Allena, Marta, Martinelli, Daniele, Guaschino, Elena, Ghiotto, Natascia, Bottiroli, Sara, Corrado, Michele, Cammarota, Francescantonio, Antoniazzi, Alessandro, Mazzotta, Elena, Pocora, Maria Magdalena, Grillo, Valentina, Sances, Grazia, Tassorelli, Cristina, and De Icco, Roberto

Published
2024
Full Text
View/download PDF

12. Additional file 1 of Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial

Author

De Icco, Roberto, Vaghi, Gloria, Allena, Marta, Ghiotto, Natascia, Guaschino, Elena, Martinelli, Daniele, Ahmad, Lara, Corrado, Michele, Bighiani, Federico, Tanganelli, Federica, Bottiroli, Sara, Cammarota, Francescantonio, Sances, Grazia, and Tassorelli, Cristina

Abstract

Additional file 1: Supplementary Table 1. Drop-outs and adverse event reporting. Supplementary Table 2. Monthly headache days, monthly migraine days and days of acute drug intake according to MIDAS and monthly migraine days (MMDs) response at T3. Supplementary Table 3. Patients’ reported outcomes according to MIDAS and monthly migraine days (MMDs) response at T3.

Published
2022
Full Text
View/download PDF

22. BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm

Author

Martinelli, Daniele, primary, Arceri, Sebastiano, additional, De Icco, Roberto, additional, Allena, Marta, additional, Guaschino, Elena, additional, Ghiotto, Natascia, additional, Bitetto, Vito, additional, Castellazzi, Gloria, additional, Cosentino, Giuseppe, additional, Sances, Grazia, additional, and Tassorelli, Cristina, additional

Published
2021
Full Text
View/download PDF

38. Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study.

Author

Sara, Bottiroli, De Icco, Roberto, Vaghi, Gloria, Pazzi, Stefania, Guaschino, Elena, Allena, Marta, Ghiotto, Natascia, Martinelli, Daniele, Tassorelli, Cristina, and Sances, Grazia

Subjects
THERAPEUTIC use of monoclonal antibodies, PERSONALITY disorders, MIGRAINE, CHRONIC diseases, MULTIVARIATE analysis, MONOCLONAL antibodies, TREATMENT effectiveness, TREATMENT failure, QUESTIONNAIRES, AFFECTIVE disorders, DESCRIPTIVE statistics, ANXIETY disorders, ODDS ratio, DRUG side effects, LONGITUDINAL method, PSYCHOLOGICAL stress
Abstract

Background: Monoclonal antibodies (mABs) targeting the calcitonin gene-related peptide (CGRP) pathway represent the first disease-specific preventive migraine therapy. Growing evidence suggests that they are effective in the preventive treatment of difficult-to-treat patients. In this study, we evaluated the psychological predictors of the outcome of treatment with the anti-CGRP monoclonal antibody erenumab in patients with chronic migraine (CM). Methods: Seventy-five patients with CM who had already failed at least 3 preventive therapies received erenumab every 28 days for a period of 12 months. Before the first administration, patients received a full psychological evaluation using The Structured Clinical Interview for DSM-5 Clinician Version (SCID-5-CV) to assess personality disturbances (primary outcome), mood and anxiety disorders, and as well specific questionnaires to evaluate alexithymia traits, childhood traumas, and current stressors (secondary outcomes). Results: After 12 months of treatment, 53 patients reported a reduction of at least 50% in headache days/per month (Responders), whereas 22 did not (Non Responders). When compared to Responders, Non Responders were characterized by a higher prevalence of personality disorders belonging to Cluster C (avoidant, dependent, and obsessive-compulsive) (77% vs 37%, p =.001). Non Responders were also characterized by a higher prevalence of anxiety disorders (90% vs 60%, p = 0.007), showed more alexithymic traits (51.7 ± 13.7 vs 42.9 ± 14.3, p = 0.017), and reported a higher number of 'at least serious' current stressors (3.2 ± 4.0 vs 0.8 ± 1.4, p <.0001) than Responders. At the multivariate analysis, higher prevalence of Cluster C personality disorders (OR 3.697; p = 0.05) and higher number of 'at least serious' life events (OR 1.382; p = 0.017) arose as prognostic factors of erenumab failure. Conclusions: Erenumab confirmed its effectiveness in a population of difficult-to-treat migraine. The presence of "anxious-fearful" personality together with current stressors and anxiety represent negative predictors of treatment outcome. Trial registration: The study protocol was registered at clinicaltrials.gov (NCT04361721). [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

39. Supplementary Tables -Supplemental material for Factors associated to chronic migraine with medication overuse: A cross-sectional study

Author

Viana, Michele, Bottiroli, Sara, Sances, Grazia, Ghiotto, Natascia, Allena, Marta, Guaschino, Elena, Nappi, Giuseppe, and Tassorelli, Cristina

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, Neuroscience, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, Supplementary Tables for Factors associated to chronic migraine with medication overuse: A cross-sectional study by Michele Viana, Sara Bottiroli, Grazia Sances, Natascia Ghiotto, Marta Allena, Elena Guaschino, Giuseppe Nappi and Cristina Tassorelli in Cephalalgia

Published
2018
Full Text
View/download PDF

42. Clinical Subtypes of Medication Overuse Headache – Findings From a Large Cohort.

Author

Viana, Michele, De Icco, Roberto, Allena, Marta, Sances, Grazia, Højland, Jensen Rigmor, Katsarava, Zaza, Lainez, Miguel J. A., Fadic, Ricardo, Goicochea, Maria Teresa, Nappi, Giuseppe, Tassorelli, Cristina, Sandrini, Giorgio, Guaschino, Elena, Ghiotto, Natascia, Munksgaard, Signe B, Rapsch, Marina, Lopez, Beatriz, Cerquetti, Daniel, Shand, Beatriz, and Osa, Maria

Subjects
ANXIETY diagnosis, DIAGNOSIS of mental depression, HEADACHE diagnosis, FUNCTIONAL assessment, MEDICATION overuse headache, HEALTH facilities, INTERVIEWING, LONGITUDINAL method, MARITAL status, RESEARCH methodology, SCIENTIFIC observation, QUESTIONNAIRES, TRYPTAMINE, PHENOTYPES, SYMPTOMS, EDUCATIONAL attainment, BODY mass index, DISEASE prevalence, CROSS-sectional method, DISEASE duration, ERGOTAMINE (Drug)
Abstract

Background: The International Classification of Headache Disorders lists different subtypes of medication overuse headache (MOH), according to the medication overused. The aim of this study is to evaluate whether the different subtypes correspond to clinically distinguishable phenotypes in a large population. Method: This descriptive cross‐sectional observational study included 660 patients with MOH referred to headache centers in Europe and Latin America as a part of the COMOESTAS project. Information about clinical features was collected with structured patient interviews and with self‐administered questionnaires for measuring disability, anxiety, and depression. Results: Female/male ratio, body mass index, marital status, and level of education were similar among in subjects enrolled in the 5 centers. The mean age was higher among subjects overusing triptans (T‐MOH) with respect to subjects overusing simple analgesic (A‐MOH). Duration of headache before chronification was longer in T‐MOH (19.2 ± 11.9 years) and in subjects overusing ergotamines (E‐MOH, 17.8 ± 11.7 years) with respect to the A‐MOH group (13.1 ± 10.9; P < .001 and P = .017, respectively) and in T‐MOH with respect multiple drug classes (M‐MOH, 14.9 ± 11.7; P = .030). Migraine Disability Assessment (MIDAS) score was significantly lower in E‐MOH group (33.6 ± 41.6), while T‐MOH group (56.8 ± 40.6) had a significant lower MIDAS score with respect to M‐MOH (67.2 ± 62.5; P = .016 and P = .037, respectively). Prevalence of depression and anxiety was lower in patients overusing T with respect to other groups of patients (χ2  = 10.953, P = .027 and χ2 = 25.725, P < .001, respectively). Conclusion: In this study on a large and very well characterized population of MOH, we describe the distinctive clinical characteristics of MOH subtypes. These findings contribute to more clearly define the clinical picture of a poorly delineated headache disorder. They also provide some insights in the possible trajectories leading to this highly disabling chronic headache, that is classified as a secondary form, but whose occurrence is entirely dependent on an underlying primary headache. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results